|
1
|
LeBlanc MM, Giguère S, Lester GD, Brauer K
and Paccamonti DL: Relationship between infection, inflammation and
premature parturition in mares with experimentally induced
placentitis. Equine Vet J. (Suppl)41:8–14. 2012. View Article : Google Scholar
|
|
2
|
Menter DG and Dubois RN: Prostaglandins in
cancer cell adhesion, migration, and invasion. Int J Cell Biol.
2012:7234192012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Granado-Serrano AB, Martín MÁ, Bravo L,
Goya L and Ramos S: Quercetin attenuates TNF-induced inflammation
in hepatic cells by inhibiting the NF-κB pathway. Nutr Cancer.
4:588–598. 2012.PubMed/NCBI
|
|
4
|
Sasaki Y, Kamei D, Ishikawa Y, et al:
Microsomal prostaglandin E synthase-1 is involved in multiple steps
of colon carcinogenesis. Oncogene. 24:2943–2952. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thiel A, Narko K, Heinonen M, et al:
Inhibition of cyclooxygenase-2 causes regression of gastric
adenomas in trefoil factor 1 deficient mice. Int J Cancer.
131:1032–1041. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hoellen F, Kelling K, Dittmer C, Diedrich
K, Friedrich M and Thill M: Impact of cyclooxygenase-2 in breast
cancer. Anticancer Res. 12:4359–4367. 2011.PubMed/NCBI
|
|
7
|
Nadda N, Vaish V, Setia S and Sanyal SN:
Angiostatic role of the selective cyclooxygenase-2 inhibitor
etoricoxib (MK0663) in experimental lung cancer. Biomed
Pharmacother. 66:474–483. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Smith KA, Tong X, Abu-Yousif AO, Mikulec
CC, Gottardi CJ, Fischer SM and Pelling JC: UVB radiation-induced
β-catenin signaling is enhanced by COX-2 expression in
keratinocytes. Mol Carcinog. 51:734–745. 2012.
|
|
9
|
Phutthaphadoong S, Yamada Y, Hirata A, et
al: Chemopreventive effect of fermented brown rice and rice bran
(FBRA) on the inflammation-related colorectal carcinogenesis in
ApcMin/+ mice. Oncol Rep. 1:53–59.
2010.PubMed/NCBI
|
|
10
|
Bai XM, Jiang H, Ding JX, et al:
Prostaglandin E2 upregulates survivin expression via the EP1
receptor in hepatocellular carcinoma cells. Life Sci. 86:214–223.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang L, Jiang L, Sun QY, Peng T, Lou KX,
Liu NB and Leng J: Prostaglandin E2 enhances mitogenactivated
protein kinase/Erk pathway in human cholangiocarcinoma cells:
involvement of EP1 receptor, calcium and EGF receptors signaling.
Mol Cell Biochem. 305:19–26. 2007. View Article : Google Scholar
|
|
12
|
Wu T: Cyclooxygenase-2 and prostaglandin
signaling in cholangiocarcinoma. Biochim Biophys Acta.
1775:135–150. 2005.
|
|
13
|
Kotelevets L, Foudi N, Louedec L,
Couvelard A, Chastre E and Norel X: A new mRNA splice variant
coding for the human EP3-I receptor isoform. Prostaglandins Leukot
Essent Fatty Acids. 77:195–201. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Regan JW, Bailey TJ, Donello JE, et al:
Molecular cloning and expression of human EP3 receptors: evidence
of three variants with differing carboxyl termini. Br J Pharmacol.
112:377–385. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schmid A, Thierauch KH, Schleuning WD and
Dinter H: Splice variants of the human EP3 receptor for
prostaglandin E2. Eur J Biochem. 228:23–30. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kotani M, Tanaka I, Ogawa Y, et al:
Molecular cloning and expression of multiple isoforms of human
prostaglandin E receptor EP3 subtype generated by alternative
messenger RNA splicing: multiple second messenger systems and
tissue-specific distributions. Mol Pharmacol. 48:869–879. 1995.
|
|
17
|
Kotani M, Tanaka I, Ogawa Y, et al:
Multiple signal transduction pathways through two prostaglandin E
receptor EP3 subtype isoforms expressed in human uterus. J Clin
Endocrinol Metab. 85:4315–4322. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Israel DD and Regan JW: EP(3) prostanoid
receptor isoforms utilize distinct mechanisms to regulate ERK 1/2
activation. Biochim Biophys Acta. 4:238–245. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rydziel S, Delany AM and Canalis E:
AU-rich elements in the collagenase 3 mRNA mediate stabilization of
the transcript by cortisol in osteoblasts. J Biol Chem.
279:5397–5404. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Malz M, Weber A, Singer S, et al:
Overexpression of far upstream element binding proteins: a
mechanism regulating proliferation and migration in liver cancer
cells. Hepatology. 50:1130–1139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Weber A, Kristiansen I, Johannsen M, et
al: The FUSE binding proteins FBP1 and FBP3 are potential c-myc
regulators in renal, but not in prostate and bladder cancer. BMC
Cancer. 8:3692008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chung HJ, Liu J, Dundr M, Nie Z, Sanford S
and Levens D: FBPs are calibrated molecular tools to adjust gene
expression. Mol Cell Biol. 26:6584–6597. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rabenhorst U, Beinoraviciute-Kellner R,
Brezniceanu ML, et al: Overexpression of the far upstream element
binding protein 1 in hepatocellular carcinoma is required for tumor
growth. Hepatology. 4:1121–1129. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Andersen SS: Spindle assembly and the art
of regulating micro-tubule dynamics by MAPs and Stathmin/Op18.
Trends Cell Biol. 10:261–267. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Singer S, Malz M, Herpel E, Warth A,
Bissinger M, Keith M, Muley T, Meister M, Hoffmann H, Penzel R,
Gdynia G, Ehemann V, Schnabel PA, Kuner R, Huber P, Schirmacher P
and Breuhahn K: Coordinated expression of stathmin family members
by far upstream sequence element-binding protein-1 increases
motility in non-small cell lung cancer. Cancer Res. 6:2234–2243.
2009. View Article : Google Scholar
|
|
26
|
He LS, Liu JH, Collins I, et al: Loss of
FBP function arrests cellular proliferation and extinguishes c-myc
expression. EMBO J. 5:1034–1044. 2000.PubMed/NCBI
|
|
27
|
Liu J, Kouzine F, Nie Z, et al: The
FUSE/FBP/FIR/TFIIH system is a molecular machine programming a
pulse of c-myc expression. EMBO J. 10:2119–2130. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Avigan MI, Strober B and Levens D: A far
upstream element stimulates c-myc expression in undifferentiated
leukemia cells. J Biol Chem. 30:18538–18545. 1990.PubMed/NCBI
|
|
29
|
Hsiao HH, Nath A, Lin CY, et al:
Quantitative characterization of the interactions among c-myc
transcriptional regulators FUSE, FBP, and FIR. Biochemistry.
49:4620–4634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wierstra I and Alves J: The c-myc
promoter: still MysterY and challenge. Adv Cancer Res. 99:113–333.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jang M, Park BC, Kang S, et al: Far
upstream element-binding protein-1, a novel caspase ubstrate, acts
as a cross-talker between apoptosis and the c-myc oncogene.
Oncogene. 28:1529–1536. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang X, Avigan M and Norgren RB:
FUSE-binding protein is developmentally regulated and is highly
expressed in mouse and chicken embryonic brain. Neurosci Lett.
252:191–194. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ko HS, Kim SW, Sriram SR, Dawson VL and
Dawson TM: Identification of far upstream element-binding protein-1
as an authentic Parkin substrate. J Biol Chem. 281:16193–16196.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Duncan RD, Bazar L, Michelotti G, et al: A
sequence-specific, single-strand binding protein activates the far
upstream element of c-myc and defines a new DNA-binding motif.
Genes. 8:465–480. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bazar L, Harris V, Sunitha I, Hartmann D
and Avigan MI: A transactivator of c-myc is coordinately regulated
with the protooncogene during cellular growth. Oncogene.
10:2229–2238. 1995.PubMed/NCBI
|
|
36
|
Yamaki T, Endoh K, Miyahara M, et al:
Prostaglandin E2 activates Src signaling in lung adenocarcinoma
cell via EP3. Cancer Lett. 214:115–120. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yutaka S, Mami T, Nobuo T, et al:
Prostaglandin E receptor EP3 deficiency modifies tumor outcome in
mouse two-stage skin carcinogenesis. Carcinogenesis. 26:2116–2122.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Finetti F, Solito R, Morbidelli L,
Giachetti A, Ziche M and Donnini S: Prostaglandin E2
regulates angiogenesis via activation of fibroblast growth factor
receptor-1. J Biol Chem. 283:2139–2146. 2008.
|
|
39
|
Gutierrez DV, Mark MD, Masseck O, et al:
Optogenetic control of motor coordination by
Gi/o protein-coupled vertebrate rhodopsin in
cerebellar Purkinje cells. J Biol Chem. 286:25848–25858. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Deng J, Liu S, Zou L, Xu C, Geng B and Xu
G: Lipolysis response to endoplasmic reticulum stress in adipose
cells. J Biol Chem. 287:6240–6249. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
McCarthy TL, Pham TH, Knoll BI and
Centrella M: Prostaglandin E2 increases transforming
growth factor-β type III receptor expression through CCAAT
enhancer-binding protein δ in osteoblasts. Mol Endocrinol.
11:2713–2724. 2007.PubMed/NCBI
|
|
42
|
Massague J, Blain SW and Lo RS: TGFbeta
signaling in growth control, cancer, and heritable disorders. Cell.
103:295–309. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shi Y and Massague J: Mechanisms of
TGF-beta signaling from cell membrane to the nucleus. Cell.
113:685–700. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Akhurst RJ and Derynck R: TGF-beta
signaling in cancer - a double-edged sword. Trends Cell Biol.
11:S44–S51. 2001.PubMed/NCBI
|
|
45
|
Derynck R, Akhurst RJ and Balmain A:
TGF-beta signaling in tumor suppression and cancer progression. Nat
Genet. 29:117–129. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wakefield LM and Roberts AB: Learning
together: clinical skills teaching for medical and nursing
students. Curr Opin Genet. 12:22–29. 2002.
|
|
47
|
Pierce DF Jr, Johnson MD, et al:
Inhibition of mammary duct development but not alveolar outgrowth
during pregnancy in transgenic mice expressing active TGF-beta 1.
Genes Dev. 7:2308–2317. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cui W, Fowlis DJ, Bryson S, et al:
TGFbeta1 inhibits the formation of benign skin tumors, but enhances
progression to invasive spindle carcinomas in transgenic mice.
Cell. 86:531–542. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bottinger EP, Jakubczak JL, Haines DC,
Bagnall K and Wakefield LM: Transgenic mice overexpressing a
dominant-negative mutant type II transforming growth factor β
receptor show enhanced tumorigenesis in the mammary gland and lung
in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene.
Cancer Res. 57:5564–5570. 1997.
|
|
50
|
Gorska AE, Joseph H, Derynck R, Moses HL
and Serra R: Dominant-negative interference of the transforming
growth factor beta type II receptor in mammary gland epithelium
results in alveolar hyperplasia and differentiation in virgin mice.
Cell Growth Differ. 9:229–238. 1998.
|
|
51
|
Engle SJ, Hoying JB, Boivin GP, Ormsby I,
Gartside PS and Doetschman T: Transforming growth factor beta1
suppresses nonmetastatic colon cancer at an early stage of
tumorigenesis. Cancer Res. 59:3379–3386. 1999.PubMed/NCBI
|
|
52
|
Zhu Y, Richardson JA, Parada LF and Graff
JM: Smad3 mutant mice develop metastatic colorectal cancer. Cell.
94:703–714. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Xu X, Brodie SG, Yang X, et al: Haploid
loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis
and cancer in mice. Oncogene. 19:1868–1874. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tang B, Bottinger EP, Jakowlew SB, et al:
Transforming growth factor-beta1 is a new form of tumor suppressor
with true haploid insufficiency. Nat Med. 4:802–807. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Han C, Demetris AJ, Liu Y, Shelhamer JH
and Wu T: Transforming growth factor-β (TGF-β) activates cytosolic
phospholipase A2α (cPLA2α)-mediated prostaglandin
E2 (PGE)2/EP1 and peroxisome proliferator-activated
receptor-γ (PPAR-γ)/Smad signaling pathways in human liver cancer
cells. A novel mechanism for subversion of TGF-β-induced
mitoinhibition. J Biol Chem. 43:44344–44354. 2004.
|
|
56
|
Markowitz SD, Itzkowitz SH and Berger BM:
The effectiveness of colonoscopy in reducing mortality from
colorectal cancer. Ann Intern Med. 150:816–817. 2009. View Article : Google Scholar
|
|
57
|
Chowdhury S, Howell GM, Rajput A, et al:
Identification of a novel TGFβ/PKA signaling transduceome in
mediating control of cell survival and metastasis in colon cancer.
PLoS One. 5:e193352011.
|
|
58
|
Liu X, Sun S and Ostrom R: Fibrotic lung
fibroblasts show blunted inhibition by cAMP due to deficient cAMP
response element-binding protein phosphorylation. J Pharmacol Exp
Ther. 2:678–687. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Schiller M, Verrecchia F and Mauviel A:
Cyclic adenosine 3′,5′,-monophosphate-elevating agents inhibit
transforming growth factor-beta-induced SMAD¾-dependent
transcription via a protein kinase A-dependent mechanism. Oncogene.
22:8881–8890. 2003.
|
|
60
|
Kim MJ, Park BJ, Kang YS, Kim HJ, Park JH
and Kang JW: Downregulation of FUSE-binding protein and c-myc by
tRNA synthetase cofactor p38 is required for lung cell
differentiation. Nat Genet. 34:330–336. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kim JY, Kang YS, Lee JW, Kim HJ, Ahn YH,
Park H, Ko YG and Kim S: p38 is essential for the assembly and
stability of macromolecular tRNA synthetase complex: implications
for its physiological significance. Proc Natl Acad Sci USA.
99:7912–7916. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Liu J, Chung HJ, Vogt M, et al: JTV1
co-activates FBP to induce USP29 transcription and stabilize p53 in
response to oxidative stress. EMBO J. 30:846–858. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Sampath P, Mazumder B, Seshadri V, et al:
Noncanonical function of glutamyl-prolyl-tRNA synthetase:
genespecific silencing of translation. Cell. 119:195–208. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Park SG, Kang YS, Ahn YH, et al:
Dose-dependent biphasic activity of tRNA synthetase-associating
factor, p43, in angiogenesis. J Biol Chem. 277:45243–45248. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Han JM, Park BJ, Park SG, et al:
AIMP2/p38, the scaffold for the multi-tRNA synthetase complex,
responds to genotoxic stresses via p53. Proc Natl Acad Sci USA.
105:11206–11211. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Corti O, Hampe C, Koutnikova H, et al: p38
subunit of the aminoacyl-tRNA synthetase complex is a Parkin
substrate: linking protein biosynthesis and neurodegeneration. Hum
Mol Genet. 12:1427–1437. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Ko HS, Coelln R, Sriram SR, et al:
Accumulation of the authentic parkin substrate aminoacyl-tRNA
synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell
death. J Neurosci. 25:7968–7978. 2005. View Article : Google Scholar : PubMed/NCBI
|
